Eqrx Inc - EQRX STOCK NEWS

EQRx, Inc. (Nasdaq: EQRX) announced that it will hold a conference call and webcast on May 8, 2023, at 4:30 p.m. ET to discuss its first quarter 2023 financial results and provide a business update. EQRx focuses on developing innovative medicines for prevalent diseases such as cancer and immune-inflammatory conditions. The company aims to enhance access to its products through cutting-edge science, technology, and strategic partnerships. Investors can join the call via a registration link to receive dial-in information, and a replay will be available on the company’s website approximately two hours post-event. This event will be critical for stakeholders looking to gauge EQRx's financial health and strategic direction.

EQRx, Inc. reported its fourth quarter and full-year financial results for 2022, ending with $1.4 billion in cash, providing a runway into 2028. The company anticipates operational cash usage to be under $275 million in 2023, aided by cost-efficiency measures including an 18% workforce reduction. Key pipeline developments include ongoing Phase 2 trials for lerociclib in breast cancer and the initiation of Phase 3 trials for advanced endometrial cancer. Marketing authorization applications for aumolertinib and sugemalimab have been accepted for review by EMA and MHRA.

EQRx, a pharmaceutical company focused on providing innovative medicines for conditions like cancer and immune-inflammatory diseases, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 4:30 p.m. PST / 7:30 p.m. EST. The event will include a live and archived webcast accessible via the company’s website. Since its launch in January 2020, EQRx has aimed to enhance access to medicines through advanced science and strategic collaborations.

EQRx announced that the U.K. Medicines and Healthcare products Regulatory Agency has accepted its marketing authorization application for sugemalimab in combination with chemotherapy as a first-line treatment for metastatic non-small cell lung cancer (NSCLC). This marks EQRx’s second application submitted to the MHRA this year, following aumolertinib. The MAA is supported by data from the Phase 3 GEMSTONE-302 trial, which showed significant improvement in progression-free survival. Sugemalimab is also under investigation for multiple cancers and has received breakthrough designations.

EQRx has submitted its first marketing authorization application (MAA) to the European Medicines Agency (EMA) for aumolertinib, a third-generation EGFR tyrosine kinase inhibitor aimed at treating EGFR-mutated non-small cell lung cancer (NSCLC). This application is based on data from the pivotal Phase 3 AENEAS trial, which evaluated aumolertinib compared to gefitinib. The acceptance by the EMA marks a significant milestone for EQRx, as approximately 60,000 patients in Europe could benefit from this treatment annually.

EQRx, Inc. (EQRX) has provided key updates regarding its drug pipeline and financial position. Aumolertinib is advancing toward a potential U.S. regulatory filing in 2027, while the company will discontinue U.S. development efforts for sugemalimab in combination with chemotherapy, citing lack of a viable path. EQRx emphasizes a market-based pricing strategy for aumolertinib and lerociclib. Financially, EQRx holds $1.5 billion in cash, with an extended runway into 2028 but reports a net loss of $85.1 million for Q3 2022, up from $39.9 million the previous year.

EQRx, a pioneering pharmaceutical company, will present a fireside chat at the Jefferies 2022 London Healthcare Conference on November 17, 2022, at 1:30 PM GMT / 8:30 AM EST. This event highlights EQRx's commitment to providing innovative medicines at lower costs. Interested parties can access a live and archived webcast on the company's website under the News & Events section. Since its launch in January 2020, EQRx has aimed to disrupt high-cost drug categories through strategic partnerships and advanced technology.

EQRx, a pharmaceutical company focused on providing innovative medicines at lower prices, announces a conference call on November 10, 2022, at 8:00 a.m. ET, to discuss Q3 2022 financial results and business updates. Interested participants can access the live webcast on the company's Investor Relations page. Founded in January 2020, EQRx aims to efficiently develop medicines and has a growing catalog in high-cost drug categories, leveraging partnerships across the healthcare system.

EQRx has initiated a Phase 3b clinical trial for aumolertinib, targeting EGFR-mutated non-small cell lung cancer (NSCLC). The UK MHRA has accepted EQRx's first regulatory submission for aumolertinib, with a US submission anticipated in the second half of 2022. New clinical data presented shows aumolertinib's significant efficacy in reducing CNS progression. EQRx reports cash reserves of $1.6 billion, sufficient to fund operations through at least 2025, despite a net loss of $82.5 million for Q2 2022.